The Hikma Pharmaceuticals Plc Board is recommending an interim dividend of 36 cents per share (H1 2024: 32 cents per share). The interim dividend will be paid on Thursday 18 September 2025 to eligible shareholders on the register at the close of business on Friday 15 August 2025.
Other financial highlights include:
Group revenue up 6% driven by robust volumes across all segments and geographies
o Injectables revenue up 12% driven by good performances in Europe (up 26%), MENA (up 16%) and North America (up 8%), supported by recent launches and the Xellia portfolio
o Branded revenue up 4% as they continue to increase market share across MENA
o Hikma Rx revenue down 1%, as expected, with differentiated portfolio performing well
Group core operating profit down 7% but continue to expect strong growth in H2
o Injectables core operating profit down 7% (down 4% in constant currency) and core operating margin of 30.0%, reflecting evolving product mix and appreciation of the Euro
o Hikma Rx core operating profit down 12% vs strong H1 2024, with 17.6% core operating margin
o Branded core operating profit up 3% (up 1% in constant currency), with core operating margin of 30.4%, reflecting the usual weighting of costs to the second half of the year
o Reported Group operating profit of $259 million, down 26%, impacted by the non-core legal settlement related to sodium oxybate
Robust balance sheet, cashflow and dividend growth
o Cashflow from operating activities of $161 million (H1 2024: $198 million)
o Net debt to core EBITDA of 1.7x at 30 June 2025 (31 December 2024: 1.4x)
